American Society of Hirudotherapy

New therapeutic options in deep vein thrombosis prophylaxis

Review published in Seminars in hematology (2000)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentEriksson BI et al. · Seminars in hematology, 2000

Abstract

Joint replacement surgery is complicated by a high rate of postoperative venous thromboembolism (VTE). Current thromboprophylactic approaches reduce the rate of VTE, but the incidence remains as high as 20% to 50%. Recombinant hirudins, such as desirudin and lepirudin, function by directly inhibiting thrombin, and are a new development in antithrombotic therapy. In two multicenter studies, desirudin was found to be superior to unfractionated heparin (UFH) in the prevention of deep vein thrombosis (DVT) after total hip alloplasty. A further trial of more than 2,000 patients undergoing elective hip replacement compared the thromboprophylactic efficacy of desirudin versus the low-molecular-weight heparin (LMWH) enoxaparin. Desirudin was more effective than LMWH in providing effective prophylaxis, and maintained superiority in patients with additional risk. Desirudin was shown to be equally safe and did not require laboratory monitoring. Desirudin (15 mg twice daily) is an efficient therapy for DVT prevention in hip alloplasty patients at additional risk.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleReview
Indexed MeSH termsArthroplasty, Replacement, HipCost-Benefit AnalysisDrug CostsFibrinolytic AgentsHeparin, Low-Molecular-WeightHirudin TherapyHirudinsHumansRecombinant ProteinsVenous Thrombosis

Summary

Review of thromboprophylaxis after joint replacement highlighting recombinant hirudins: desirudin outperformed unfractionated heparin and, in a trial of over 2,000 hip replacement patients, enoxaparin, maintaining superiority in higher-risk patients without laboratory monitoring at 15 mg twice daily.

Why This Matters for Hirudotherapy

This article discusses newer pharmacological options for preventing postoperative venous thromboembolism following joint replacement surgery, focusing on recombinant hirudins such as desirudin and lepirudin, which the abstract states function by directly inhibiting thrombin. The abstract reports multicenter study data showing desirudin was superior to unfractionated heparin and more effective than the low-molecular-weight heparin enoxaparin in preventing deep vein thrombosis after elective hip replacement, without requiring laboratory monitoring. The abstract does not mention leeches, leech saliva, or any leech secretome, identifying the drugs only as 'recombinant hirudins,' so the connection to applied hirudotherapy is not established by this article. The scope is limited to pharmaceutical thromboprophylaxis in surgical patients.

Citation

Reference (Vancouver style)

Eriksson BI. New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000;37(3 Suppl 5):7-9. doi:10.1016/s0037-1963(00)90093-3. PMID: 11055889

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.